Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track FTH with free AI briefings, catalyst countdowns, and dilution alerts.

FTH · Faeth Therapeutics, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$174.8M Cash on Hand
36.6mo Cash Runway
5.2% Short Interest
$56.67 Analyst Target (12)
Follow FTH by email Get an email when FTH reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about FTH, unsubscribe in one click. Privacy

📣 What FTH Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Sapanisertib Endometrial Cancer Phase 2 · NCT06463028 Recruiting
Serabelisib Endometrial Cancer Phase 2 · NCT06463028 Recruiting
Nab-paclitaxel Advanced Solid Tumor Phase 1 · NCT05300048 Terminated

Also used in these trials (approved or third-party drugs, not FTH's own candidates): Fulvestrant, Paclitaxel.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

FTH holds $174.8M in cash and short-term investments (as of Sep 30, 2026) and burns about $14.3M/quarter from operations, an estimated runway of 36.6 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 25 · Moderate

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when FTH files for a raise →

👥 Who Owns FTH

Insiders 9% Other 5%+ holders 20.2% Institutions (66 holders) 70.8% Public and other holders 0%
HolderTypeShares% of sharesAs of
VK Services, LLC 5%+ holder (13G) 2,632,232 10.19% 2026-06-15
S2G Investments, LLC 5%+ holder (13G) 2,575,401 9.97% 2026-06-15
Montanova Capital, LLC Institution (13G, 5%+) 2,310,703 8.94% 2026-09-30
Suvretta Capital Management, LLC Institution (13G, 5%+) 2,020,103 7.82% 2026-06-15
Avoro Capital Advisors LLC Institution (13G, 5%+) 1,410,000 5.46% 2026-09-30
Baker Bros. Advisors, LP Institution (13F) 1,286,411 4.98% 2026-06-30
Balyasny Asset Management LP Institution (13F) 1,042,198 4.03% 2026-06-30
Cormorant Asset Management, LP Institution (13F) 1,028,242 3.98% 2026-06-30
Khosla Ventures VI, L.P.
10% owner
Insider 988,883 3.83% 2026-06-15
Anand Kiran Parikh
President and CEO, Director · +1.73M options
Insider 817,699 3.16% 2026-10-30
RA Capital Management, L.P. Institution (13F) 722,020 2.79% 2026-06-30
Vivo Capital, LLC Institution (13F) 722,020 2.79% 2026-06-30

Share count 25,843,945 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-06-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Trade dateInsiderTransactionSharesPriceOwned after
2026-09-11
filed 2026-09-15
Vousden Karen H
Option award (A) 25,000 – –
2026-07-21
filed 2026-07-23
Parikh Anand Kiran
Option award (A) 398,018 – –
2026-07-21
filed 2026-07-23
Craver Josiah
Option award (A) 30,824 – –
2026-07-01
filed 2026-07-01
STEPHENSON BRIAN C
Purchase (P) 600 $24.22 46,688
2026-07-01
filed 2026-07-01
STEPHENSON BRIAN C
Purchase (P) 4,400 $23.40 46,088

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

Get the full FTH picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for FTH and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.